KaloCyte, Inc.
KaloCyte, Inc. is a pre-clinical stage biotech company focused on developing ErythroMer™, a dried, bio-inspired artificial red blood cell that is shelf-stable without refrigeration. This innovative solution aims to address the critical need for blood substitutes in emergency situations where stored red blood cells are unavailable, undesirable, or in short supply. Founded by a team of experts in physiology, bioengineering, and trauma care, KaloCyte is supported by significant federal grants and investor funding, positioning it to advance to first-in-human trials.
KaloCyte, Inc.
670 West Baltimore Street, HSRF III, 8th Floor, Baltimore, Maryland 21201
KaloCyte, Inc. is currently seeking investment
KaloCyte, Inc. is seeking a series-a investment in the range of 5m-20m
What We Do
A dried, bio-inspired artificial red blood cell designed to treat life-threatening blood loss when stored red blood cells are unavailable, undesirable, or in short supply. ErythroMer has the potential to save lives in pre-hospital settings and on the battlefield.
Biologics
Key People
News & Updates
A new candidate, ErythroMer, is still in preclinical testing but could be more durable and versatile than the real thing.
The research park’s location and resources make it invaluable for life science startups.
Elaine Haynes discusses KaloCyte’s groundbreaking bio-inspired artificial red blood cells.
KaloCyte is a partner in a $46 million project led by the University of Maryland School of Medicine to develop an artificial whole blood product.
nnals of Medicine The Long Quest for Artificial Blood One of the most valuable substances in the world has never been replicated. Are we close? By Nicola Twilley February 3, 2025
BALTIMORE, January 28, 2025 – KaloCyte, Inc., a pre-clinical biotech startup company developing a bio-inspired red blood cell substitute called ErythroMer™, announced today that it has been selected to join Blue Knight, a strategic collaboration between the Biomedical Advanced Research and Development Authority ('BARDA') and Johnson & Johnson’s global incubator network, JLABS, supporting early-stage innovation and incubation of science and technologies to improve health security and unlock new approaches to solving health issues. KaloCyte, a University of Maryland BioPark affiliate, will be a virtual resident within JLABS, a premier life science incubator program. They will keep their laboratories and offices in downtown Baltimore where they collaborate closely with the University of Maryland School of Medicine’s Center for Blood Oxygen Transport & Hemostasis (CBOTH).